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ABSTRACT: For complex traits, most associated single nucleotide variants (SNV) discovered to date have a small effect, and
detection of association is only possible with large sample sizes. Because of patient confidentiality concerns, it is often not
possible to pool genetic data from multiple cohorts, and meta-analysis has emerged as the method of choice to combine results
frommultiple studies. Many meta-analysis methods are available for single SNV analyses. As new approaches allow the capture
of low frequency and rare genetic variation, it is of interest to jointly consider multiple variants to improve power. However,
for the analysis of haplotypes formed by multiple SNVs, meta-analysis remains a challenge, because different haplotypes
may be observed across studies. We propose a two-stage meta-analysis approach to combine haplotype analysis results. In
the first stage, each cohort estimate haplotype effect sizes in a regression framework, accounting for relatedness among
observations if appropriate. For the second stage, we use a multivariate generalized least square meta-analysis approach to
combine haplotype effect estimates frommultiple cohorts. Haplotype-specific association tests and a global test of independence
between haplotypes and traits are obtained within our framework. We demonstrate through simulation studies that we control
the type-I error rate, and our approach is more powerful than inverse variance weighted meta-analysis of single SNV analysis
when haplotype effects are present. We replicate a published haplotype association between fasting glucose-associated locus
(G6PC2) and fasting glucose in seven studies from the Cohorts for Heart and Aging Research in Genomic Epidemiology
Consortium and we provide more precise haplotype effect estimates.
Genet Epidemiol 40:244–252, 2016. © 2016 Wiley Periodicals, Inc.
KEY WORDS: meta-analysis; haplotype association tests; family samples; linear mixed effects model
Introduction
In recent years, genome-wide association studies (GWAS)
have identified multiple common variants associated with
disease and disease-related traits. In a typical GWAS, associa-
The copyright line for this article was changed on 5th May 2016 after original online
publication.
∗Correspondence to: Jose´e Dupuis, 3rd Floor, 801 Massachusetts Avenue, Boston,
MA 02118. E-mail: dupuis@bu.edu
tion between a trait and genetic variants is tested one variant
at a time, and variants with weak association routinely fail
to be detected, especially in small cohorts. Therefore, meta-
analysis is often used by large consortia to increase statistical
power [Dupuis et al., 2010, Scott et al., 2012, Stram, 1996,
Zeggini et al., 2008] to detect variants with a moderate to
weak association with the trait of interest. Even with large
meta-analyses, variants identified to date only explain a small
proportion of the total heritability. In order to identify the
C© 2016 The Authors. ∗Genetic Epidemiology Published by Wiley Periodicals, Inc.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
source of the unexplained heritability, emerging approaches
have attempted to account formultiple variants at once when
evaluating association with a trait. Such approaches include
penalized regressionmethods [Li et al., 2011,Wu et al., 2009],
pathway analysis [Holden et al., 2008], gene-based tests such
asburden [MadsenandBrowning, 2009] andSKAT[Wuet al.,
2010], and haplotype analysis [Liu et al., 2008, Schaid et al.,
2002, Tregouet et al., 2004]. The power of these approaches
can be enhanced by increasing sample size or combiningmul-
tiple studies. Methods for meta-analysis of gene-based tests
are well established and widely used [Hu et al., 2013, Liu
et al., 2014], but there are no widely used methods for the
meta-analysis of haplotype association tests.
In this article, we propose a meta-analysis approach to
combine haplotype association results from multiple stud-
ies. In the first step of our method, each study provides
regression estimates and covariance matrices of haplotype
effects, with adjustment for familial correlation to accom-
modate familial samples or cryptic relatedness. In our second
step, cohort-specific haplotype effect estimates are pooled us-
ing a multivariate generalized least square meta-analysis ap-
proach. A global association test and evaluation of the effect
of each haplotype can be obtained within our framework.
We perform a simulation study to evaluate our approach,
comparing results with more traditional meta-analysis of
single-variant association tests and gene-based tests. Finally,
we replicate a published haplotype association between a
fasting glucose-associated locus (G6PC2) and fasting glucose
in seven studies from the Cohorts for Heart and Aging Re-
search in Genomic Epidemiology (CHARGE) Consortium
and are able to provide more precise haplotype effect es-
timates than the prior report involving haplotype estimates
froma single cohort [Mahajan et al., 2015]. Code implement-
ing the novel approach, along with a tutorial, is available at
http://sites.bu.edu/fhspl/publications/metahaplo.
Methods
Haplotype Association Test at Cohort Level
Our approach is based on Zaykin et al.’s [2002] haplo-
type analysis method for unrelated samples. We incorporate
random effects to account for family structure, making the
approach applicable to family-based cohorts, unrelated sam-
ples, or a mix of the two. We assume that a total of n subjects
from a study are sequenced in a region with q SNVs and as a
result,K haplotypes are observed.We assume a general linear
(mixed-effect) model, written as:
Y = Xα + β1h1 + ... + βKhK + b + , (1)
whereY is ann × 1quantitative trait vector,X is ann × p ma-
trix of covariates (without intercept) including, for example,
age, sex, and associated genetic principal components con-
trolling for potential population stratification, α is a p × 1
coefficient vector for the p adjustment variables, each n × 1
vector hm (m = 1, · · · ,K ) is the expected haplotype dosage,
b is an n × 1 random effect vector that accounts for the re-
latedness within families, and  is an n × 1 vector of the ran-
dom error terms.When haplotypem of the j th (j = 1, · · · , n)
subject is observed, hmj , the j th entry in hm is either 0, 1, or 2,
that is, the number of copies of haplotype m the j th subject
carries. Otherwise, expected haplotype dosages E [hmj |Gj]
are inferred from Gj, the q × 1 genotype vector of the j th
subject, using statistical algorithms such as the expectation-
maximization (EM) algorithm [Dempster et al., 1977]. For
the j th subject, the sumof theK haplotypedosages
∑m=K
m=1 hmj
is always equal to 2. The n × 1 random effect vector b is as-
sumed to follow a normal distribution N(0, σ2a), where σ
2
a
is the additive variance and is the relationshipmatrix (with
entries equal to twice the kinship coefficient for related pairs
and 0 for unrelated pairs) derived from pedigree structure or
genome-wide information; in unrelated samples, the matrix
 reduces to I, the n × n identity matrix. Finally, we assume
the vector of error terms  follows a normal distribution
N(0, σ2e I), where σ
2
e is the variance of the error term.
Let Xo = (X,h1, · · · ,hK) denote the overall design matrix
of size n × (p + K ), and define the overall variance matrix
as  = σ2a + σ
2
e I. The parameters α and βk (k = 1, · · · ,K )
are estimated as (XTo ˆ
–1Xo)
–1XTo ˆ
–1Y, where ˆ is evaluated
at the maximum likelihood estimates σˆ2a and σˆ
2
e , which can
be obtained using the lmekin function in R’s coxme package
[Therneau, 2012]. The estimated variance of the effect esti-
mates is (XTo ˆ
–1Xo)
–1. The method reduces to an ordinary
linear regression when applied to unrelated samples.
Meta-Analysis
We assume a total of N cohorts participate in the meta-
analysis and the i-th (i = 1, · · · ,N) cohort provides the esti-
mates βˆi and the covariance matrix ˆvar(βˆi) of the haplotype
effects for K i haplotypes, and a total of K ′ haplotypes are
observed in at least one cohort. We propose a multivari-
ate meta-analysis approach [Becker and Wu, 2007] based on
generalized weighted least squares to combine the length K i
haplotype effect estimates from each cohort, denoted by βˆi
for studies i = 1, · · · ,N, into a single effect estimate vector β˜
of length K ′. The generalized weighted least square approach
is formulated as:
βˆ =
⎛
⎜⎝
βˆ1
...
βˆN
⎞
⎟⎠ = Wβ + e =
⎛
⎜⎜⎜⎜⎜⎜⎜⎝
1 . . . 0 . . . 0
0 . . . . . . . . . 0
0 . . . 0 . . . 1
...
...
...
...
...
1 . . . 0 . . . 0
0 . . . 0 . . . 1
⎞
⎟⎟⎟⎟⎟⎟⎟⎠
⎛
⎜⎝
β1
...
βK
′
⎞
⎟⎠ + e, (2)
where βˆi (i = 1, · · · ,N) is the K i × 1 haplotype coefficient
vector for cohort i;
βˆ is the stacked haplotype coefficient vector from βˆi (i =
1, · · · ,N);
β is the K ′ × 1 coefficient vector of the haplotype effects;
W =
⎛
⎜⎝
W1
...
WN
⎞
⎟⎠ is a∑i K i × K ′ design matrix stacked from
the N cohorts, whereWi (i = 1, · · · ,N) is a K i × K ′ matrix,
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with zeros and one in each row indicating which haplotype
effect is observed by cohort i;
e is the error term which is assumed to have a multivariate
normal distributionwith amean of 0 and a covariancematrix
of
 =
⎛
⎜⎜⎜⎝
var(βˆ1) · · · 0
... var(βˆk)
...
0 · · · var(βˆN)
⎞
⎟⎟⎟⎠.
Note that in the meta-analysis stage, cohort haplotypes are
reordered to match the order assigned to the K ′ haplotypes
observed in at least one cohort, and the design matrixW re-
flects this reordering. Furthermore, because  is unknown,
in our method, we substitute the sample estimate
ˆ =
⎛
⎜⎜⎜⎝
ˆvar(βˆ1) · · · 0
... ˆvar(βˆk)
...
0 · · · ˆvar(βˆN)
⎞
⎟⎟⎟⎠, hence the weighted least
square estimator of β is β˜ = (W′ˆ–1W)–1W′ˆ–1βˆ and
V = Var(β˜) = (W′ˆ–1W)–1.
Hypothesis Testing
The global null hypothesis of no association of any haplo-
type with the trait is expressed as
H0 : β
1 = β2 = ... = βK
′
(3)
To construct a test statistic to test for haplotype associa-
tion, we reparameterize it into the equivalent null hypothesis,
where β1 is chosen from commonly observed haplotypes:
H0 : γ =
⎛
⎜⎝
γ1
...
γK
′–1
⎞
⎟⎠ =
⎛
⎜⎝
β2 – β1
...
βK
′
– β1
⎞
⎟⎠ =
⎛
⎜⎝
0
...
0
⎞
⎟⎠ (4)
The null hypothesis can be tested using a Wald test statistic
of the form
χ2 = γˆT[V∗]–1γˆ, (5)
where γˆ is estimated from β˜ and V∗ is the covariance matrix
of γˆ, with a dimension of (K ′ – 1) × (K ′ – 1) and the j j ′th
element having the form V∗j j ′ = Vjj ′ – Vj 1 – Vj ′1 + V11. Under
the null hypothesis, the Wald test statistic follows a χ2
K ′–1 dis-
tribution asymptotically.
Cohorts for Heart and Aging Research in Genetic
Epidemiology Consortium
TheCHARGE consortium comprisesmultiple studies with
the commongoal of identifying genes and loci associatedwith
cardiovascular-related traits. Seven CHARGE cohorts con-
tributed toameta-analysis evaluating the associationbetween
genetic variants and fasting glucose in 25,305 nondiabetic
participants (Table 1). Fasting glucose levels in millimole per
liter were analyzed in participants free of type-2 diabetes.
Type-2 diabetes was defined by cohorts referring to at least
one of the following criteria: a physician diagnosis of type-2
Table 1. CHARGE cohorts
Cohort Sample size
Generation Scotland: Scottish Family Health Studya (GS) 7,678
Framingham Heart Studya (FHS) 6,561
Cardiovascular Health Study (CHS) 3,525
Family Heart Studya (FamHS) 3,393
Multi-Ethnic Study of Atherosclerosis (MESA) 2,507
FENLAND (FLD) 1,341
European Prospective Investigation into Cancer and
Nutrition, Potsdam (EPIC-Potsdam)
300
Total 25,305
Notes aFamily-based cohort.
Table 2. Study designs for type-I error rate evaluation
Study
design
No. of
cohort Sample sizes
Type-I
error rate
(G6PC2)
Type-I
error
rate
(JAZF1)
1 5 250 NF2 (×5) 0.010 0.010
2 5 250 NFv (×5) 0.010 0.012
3 5 100 NF2, 175 NF2, 400 U, 700 U, 1000 U 0.013 0.010
4 5 100 NFv, 175 NFv, 400 U, 700 U, 1000 U 0.011 0.011
5 5 100 NFv, 175 NFv, 250 NFv, 325 NFv, 400 NFv 0.011 0.012
6 10 250 NF2 (×5); 1000 U (×5) 0.010 0.011
7 10 400 U, 700 U, 1000 U, 1300 U, 1600 U 0.008 0.012
8 5 100 NF2, 175 NF2, 250 NF2, 325 NF2, 400 NF2 0.012 0.011
9 5 250 NF2, 125 NF2 (×2), 375 NF2 (×2) 0.011 0.011
1000 U, 500 U (×2), 1500 U (×2)
10 10 250 NFv (×7), 1000 U (× 3) 0.012 0.011
Notes NF2, nuclear family with 2 offspring; NFv, nuclear family with the number of
offspring randomly selected to be between 1 and 4; U, unrelated subjects.
diabetes, on the antidiabetic treatment of type-2 diabetes,
fasting plasma glucose ≥7 mmol/l, random plasma glucose
≥11.1 mmol/l, or hemoglobin A1C ≥ 6.5%. Study-specific
sample exclusions were detailed in [Wessel et al., 2015].
Genotypeswere obtained from the IlluminaHumanExome
BeadChip [Grove et al., 2013], a genotyping array contain-
ing 247,870 variants discovered through exome sequencing in
∼ 12,000 individuals, in which∼ 75%of the variants are low-
frequency variants (Minor Allele Frequency (MAF) < 0.5%).
Themain content of the chip comprises protein-altering vari-
ants (nonsynonymous coding, splice-site, and stop gain or
loss codons) seen at least three times in a study and in at
least two studies providing information to the chip design.
We selected four G6PC2 variants previously studied for their
haplotype association with fasting glucose [Mahajan et al.,
2015].
Simulation Studies
To evaluate the validity and power of our approach, we
perform a simulation study varying the number of cohorts
included in the meta-analysis (5 or 10), and the type of sam-
ples (unrelated, family-based, mix of the two). We also vary
the sample size from 400 up to 1,600 subjects per cohort.
See Table 2 for a description of the various study designs
investigated in type-I error rate and power.
Simulated trait values are dependent on sex, age, and
haplotypes/genetic variants (power evaluation only). Sex of
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Table 3. G6PC2 variants
Name Chr MapInfo dbSNPID Minor Major FHS MAF
exm-rs560887 2 169763148 rs560887 A G 0.293
exm239664 2 169763262 rs138726309 T C 0.0036
exm239667 2 169764141 rs2232323 C A 0.0078
exm239672 2 169764176 rs492594 C G 0.4553
Table 4. G6PC2 haplotype frequencies
rs560887 rs138726309 rs2232323 rs492594 FHS frequency
C C A C 0.46
T C A G 0.29
C C A G 0.24
T C C G 0.006
C T A C < 0.001
T C A C < 0.001
C T A G < 0.001
C C C G < 0.001
Table 5. JAZF1 variants (chromosome 7)
Name Position dbSNPID Minor Major MAF
exm-rs10486567 27976563 rs10486567 A G 0.2415
exm2270592 28039797 rs38523 C T 0.3683
exm-rs864745 28180556 rs864745 G A 0.4965
exm-rs1635852 28189411 rs1635852 C T 0.4973
exm-rs849134 28196222 rs849134 G A 0.4917
mothers and fathers (founders) are fixed in a heterosexual
marriage but are randomly assigned to offspring, with equal
probability. The age for unrelated individuals and the first
offspring in a family are generated from a uniform distribu-
tion over the range 30 to 50. Additional offspring’s ages are
set to be within 5 years of the first offspring with at least a 1
year gap (no twins), using a uniform distribution. For family
samples, the age of the mother is restricted to be 20–45 years
older than her offspring, and the father’s age to be within
5 years of the mother’s age, with a restriction that the age be
at least 20 years older than the older offspring.
We select the known T2D-associated genes G6PC2 (chro-
mosome 2; Tables 3 and 4) and JAZF1 (chromosome 7;
Tables 5 and 6) to generate the reference panel haplotypes
(Tables 3 and 4). We use the observed haplotypes and fre-
quencies estimated by EM algorithm from 6561 partici-
pants from the Framingham Heart Study. For example, in
JAZF1 no single haplotype has a frequency greater than
25% and eight haplotypes have frequency greater than 1%
(Table 6).
Genotypes are simulated by randomly assigning a pair of
haplotypes to founders, and by dropping randomly selected
haplotypes to offspring assuming no recombination within
haplotypes. Although phasing information is available in our
simulation setting, we do not use the phase information
when implementing our approach because such informa-
Table 6. JAZF1 haplotype frequencies
Haplotype rs10486567 rs38523 rs864745 rs1635852 rs849134 Frequency
1 G T A T A 0.2327
2 G T G C G 0.2295
3 G C G C G 0.1608
4 G C A T A 0.1295
5 A T A T A 0.0866
6 A T G C G 0.0793
7 A C A T A 0.0434
8 A C G C G 0.0259
9 A T G T A 0.0029
10 A T A C A 0.0029
11 A C A C A 0.0023
12 G T A C A 0.0019
13 G T G T A 0.0017
14 G C G T A 0.0005
tion is not typically available in real datasets. We use the EM
algorithm to infer expected haplotype dosage conditional on
genotypes via R package haplo.stats [Sinnwell and Schaid,
2013].
When estimating haplotype effects at the cohort-level, rare
haplotypes (frequency< 0.1%) are collapsed to stabilize the
computation and to avoid potential singularities due to high
LD among SNVs.
Type-I Error Rate
For evaluating the type-I error rate of our new approach,
a trait unassociated with the haplotypes is simulated using
a multivariate normal distribution with mean μˆ = 0.02 ×
age + 0.5 × sex (sex is set to 1 for males and to 2 for females)
and a covariance matrix σ2a + σ
2
e I , with σ
2
a = σ
2
e = 0.5. Age
and sex explained about 10% and 5% of the trait variance,
respectively, resulting in a trait with moderate heritability
(h2 = σ
2
a
Var(Y) ≈ 0.42).
Cohort-specific analyses are performed by first estimat-
ing haplotypes using the EM algorithm implemented in the
R package haplo.stats, followed by regression analysis using
haplotype dosages and covariates as independent variables.
Cohort results are then meta-analyzed using the novel ap-
proach previously described, and the global association test
P values are recorded. Ten thousand simulations are per-
formed to assess the type-I error rate in all scenarios at the
nominal threshold α = 0.01 (Table 2).
Power Evaluation
The power of our novel haplotype meta-analysis approach
is evaluated in a total of 16 scenarios (phenotype datasets) di-
vided into four study designs (study design 1–4 fromTable 2),
with varying haplotype or SNV effects. For each scenario, we
first compute themeta-analysis haplotype global test statistic,
and then compare tometa-analysis of both single variant tests
and gene-based tests. For single variant tests, we compute the
meta-analysis test statistic using inverse-variance weighted
method that has been shown to be the most powerful when
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Table 7. Single haplotype association test using 4SNVs on G6PC2 region
rs560887 rs138726309 rs2232323 rs492594 β (SE) P-value Frequency βM (SE M )a
C C A C 0.4394
T C A G –0.073 (0.0055) 4.56 × 10–41 0.2671 –0.065(0.011)
C C A G 0.039 (0.0056) 5.98 × 10–12 0.2645 0.034(0.012)
T C C G –0.12 (0.029) 2.82 × 10–5 0.0065 –0.205(0.057)
C T A C –0.022 (0.056) 0.70 0.0021 –0.202(0.077)
T C A C –0.031 (0.020) 0.12 0.0195 NA
Notes The haplotypes are observed in all cohorts except that the last one is observed only in FHS, CHS, GS, and FamHS.
a βM and SE M denote the estimates from the paper of Mahajan et al. [2015].
the effect size is constant across cohorts [Zhou et al., 2011].
We then select the SNP with the minimum meta-analysis
P-value Pmin = min{1≤i≤K }Pi (K = 4 for G6PC2; K = 5 for
JAZF1) and adjust the meta-analysis P-value for multiple
testing using a Bonferroni correction for the effective num-
ber of independent variants [Gao et al., 2008]. We denote the
result for the best SNP in the single variant analysis by “min
P”. For gene-based tests, we choose SKAT and Burden test
with Wu weights and perform the analysis using R package
seqMeta [Voorman et al., 2014].We use α = 0.001 to evaluate
the power of all four approaches.
For each scenario, the phenotype is simulated using a
multivariate normal distribution with mean μˆ and a co-
variance matrix σ2a + σ
2
e I , with σ
2
a = σ
2
e = 0.5, but unlike
the type-I error scenarios, the value of μˆ depends on geno-
types/haplotypes in addition to the covariates of age and sex.
We investigate four genetic effect scenarios: one or two causal
genetic variants, or one or two causal haplotypes. For the
causal variant scenario, μˆ = 0.02 × age + 0.5 × sex + bg 1 ×
g1 + bg 2 × g2 where gj (j = 1, 2) is a vector containing the
number of minor alleles (0, 1, or 2) carried by individu-
als in the sample, and bgj is the effect of variant j , set to√
R2
4MAFj (1–MAFj )
, where MAFj is the minor allele frequency
of variant j and R2 = 0.01 is the proportion of variance
explained by this specific variant (haplotype). When only
one causal variant is included in the model, bg2 = 0 and
bg1 is multiplied by
√
2. For the causal haplotype models,
μˆ = 0.02 × age + 0.5 × sex + bh1 × h1 + bh2 × h2, where hj
is a vector containing the number (conditional dosage) of
haplotype j carried by individuals in the sample, and bhj is
the effect of haplotype j , set to
√
R2
2h¯j (1–h¯j /2)
, where h¯j is mean
haplotype dosage of haplotype j and R2 = 0.01. When only
one causal haplotype is included in themodel, bh2 = 0 and bh1
is multiplied by
√
2. For the JAZF1 gene, we select two hap-
lotypes, GTATA (the most frequent haplotype) and GCGCG
(the third most frequent haplotype), to have an effect on the
phenotype while all other haplotypes have no effect on the
phenotype. For models with single variant effects, we select
rs849134 and rs38523 to have nonzero effect on the trait,
while all other genetic variants have no effect. For the G6PC2
gene, we select CCAC and TCAG, the twomost frequent hap-
lotypes to have an effect on the phenotype. For models with
single variant effects, we select rs560887 and rs2232323 to
have nonzero effect on the trait.
A thousand simulations with five independent cohorts are
performed tocompare thepowerofour approach to the single
variant method adjusted for multiple testing and gene-based
methods.
Results
Meta-Analysis of Four Coding Variants on G6PC2 Region
G6PC2 is a known locus to affect fasting glucose level.
Among the 17 exonic variants on the exome chip, 15 are rare
variants (MAF<1%) and two are common variants (rs560887
with MAF = 25.4%; rs492594 with MAF = 43.7%). Previous
GWAS have identified the A allele of rs560887, one of the two
common variants to be associated with lower fasting glu-
cose level ([Bouatia-Naji et al., 2008]: β = –0.07 mmol/l, p =
6 × 10–16; [Dupuis et al., 2010]: β = 0.075 ± 0.003 mmol/l,
p = 8.5 × 10–122). A recent large-scale exome-chip analysis
indicated that these 15 rare variants also had a joint effect on
fasting glucose [Wessel et al., 2015]. Our approach is applied
to study the association between the haplotype structure of
four coding variants rs560887, rs138726309, rs2232323, and
rs492594 and fasting glucose, using CHARGE exome-chip
data. We perform a meta-analysis of seven studies compris-
ing of three family-based and four population-based cohorts
with up to 25,305non-diabetic Europeanparticipants, to bet-
ter understand how the overall haplotype structure as well as
how the single haplotype affect fasting glucose level. With
a meta-analysis sample size of 25,305, we have successfully
replicated a previous reported haplotype analysis of four cod-
ing variants onG6PC2 region [Mahajan et al., 2015], butwith
higher precision (Table 7). Our effect size estimates are con-
sistent with previously published estimates, in terms of both
direction and magnitude. However, prior results were based
on a single population-based cohort with 4,442 participants.
In contrast, our analysis is based on seven cohorts with over
25,000 participants. Among the five haplotypes shared by all
seven studies, one copy of the most significant haplotype,
TCAG, decreases fasting glucose levels by 0.074 (95% con-
fidence interval (CI): 0.063,0.085) mmol/l, on average; one
copy of the second most significant haplotype, CCAG, in-
creases the average fasting glucose levels by 0.039 (95% CI:
0.028,0.050) mmol/l; and one copy of the third most sig-
nificant haplotype, TCCG, decreases fasting glucose levels
by an average of 0.12 (95% CI: 0.065,0.18) mmol/l. Most
248 Genetic Epidemiology, Vol. 40, No. 3, 244–252, 2016
Figure 1. Power of the haplotype meta-analysis approach compared to gene-based methods and single SNV meta-analysis (min P) adjusted for
multiple testing in the G6PC2 region, evaluated at α = 0.001 in four study designs. Description of the four study designs used in the simulation can
be found in Table 2 (study design 1–4). The labels on the x axes denote that 1 (SNV) or 2 (2SNVs) SNVs are influencing the phenotypes, or 1 (1HAP)
or 2 (2HAPs) haplotypes have an effect on the phenotypes.
haplotype effect estimates reported in Mahajan et al. [2015]
fall within our 95 % CI, with the exception of estimates for
TCCG (Mahajan et al.’s [2015] estimates = 0.205), which fall
just outside our reported CI.
Simulations
Ten scenarios with increasing diversity in the study designs
of the cohorts included in the meta-analysis are simulated to
evaluate type-I error rate of our approach. The type-1 error
rate is well controlled in all scenarios investigated (Table 2).
In the simulations to evaluate power, our approach is
shown to be almost as powerful as the single SNV approach
when SNVs are influencing the trait, but much more power-
ful to detect true haplotype effects. For example, in the family
based design scenarios, our approach is 40% more powerful
than single SNV analyses when two haplotypes have nonzero
effect on the phenotypes (Figures 1 and 2). A similar pattern
is observed for designs with a mix of unrelated and related
samples. The gain in power is smaller when a single hap-
lotype is influencing the trait, but present for all scenarios
evaluated. When compared to the gene-based tests, our ap-
proach is uniformly more powerful in all scenarios across all
study designs (Figures 1 and 2) because of the Wu (default)
weighing scheme that downweights common variants.
Discussion
We have proposed a general meta-analysis approach to
combine the haplotype association results from multiple co-
horts. Our approach imposes no restrictions on the hap-
lotypes observed across cohorts. Instead, our approach can
incorporate information from haplotypes observed in a sin-
gle cohort in addition to haplotypes observed in multiple
cohorts. In the first stage of our approach, haplotype associ-
ation analysis is performed at the cohort level. Information
about the haplotype structure, frequencies, effect estimates,
and covariance of effect estimates is collected, and meta-
analyzed in the second stage using a generalized weighted
least square approach. The association between a trait and
any single or multiple haplotypes can be easily evaluated
within our framework.
We evaluated the type-I error rate in a variety of scenarios
with different cohort designs that included a mix of unre-
lated and family samples. Type-I error rate was controlled
in all scenarios investigated. We also compared the power of
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Figure 2. Power of the haplotype meta-analysis approach compared to gene-based methods and single SNV meta-analysis (min P) adjusted for
multiple testing in the JAZF1 region, evaluated at α = 0.001 in four study designs. Description of the four study designs used in the simulation can
be found in Table 2 (study design 1–4). The labels on the x axes denote that 1 (SNV) or 2 (2SNVs) SNVs are influencing the phenotypes, or 1 (1HAP)
or 2 (2HAPs) haplotypes have an effect on the phenotypes.
our approach with single variant tests corrected for multiple
testing (min P approach), and demonstrated that our ap-
proach had equivalent power when variants, not haplotypes,
influenced the trait, but was more powerful in the presence
of true haplotype effects. Our haplotype approach also pro-
videdmore evidence for association compared to gene-based
tests applied with the default weighting scheme, as exem-
plified in a recent large-scale exome-chip project [Wessel
et al., 2015] applied to the G6PC2 region comprising 15
rare variants (MAF<1%). Our simulations also illustrated
that the haplotype effect size estimates obtained from meta-
analysis were unbiased, evenwhen family-based cohorts were
included.
While our approach cannot serve as the only tool for the
discovery of associated variants and regions, it is a comple-
mentary tool to single-variant and gene-based tests. Mahajan
et al. [2015] demonstrated the usefulness of haplotype anal-
ysis in their investigation of the effect of G6PC2 variants on
fasting glucose. In 4,442 nondiabetic subjects from the Ox-
ford Biobank, the G allele from the coding variant rs492594
appears to significantly decrease fasting glucose levels. How-
ever, when conditioning on the variant with the largest effect
(rs560887) on fasting glucose, the effect estimates of the G-
allele from rs492594 is reversed, and the G allele appears
to decrease fasting glucose, an apparent paradox. However,
looking at the haplotype estimates elucidates themystery: the
rs492594 G allele is most frequently observed on the same
haplotype as the glucose raising allele (T) from the strongest
associated variant (rs560887), giving the impression that the
G allele also increases fasting glucose. Our analysis supports
this conclusion, and refines the effect estimates provided by
Mahajan et al. [2015] by increasing the number of samples
used to obtain effect estimates via meta-analysis, providing
more precise estimates, as reflected in the smaller standard
errors.
Our approach has some limitations. The variants included
in the haplotype analysismust be genotyped or imputed in all
cohorts. In other words, all cohortsmust include the same set
of variants in their analysis. Moreover, when using imputed
genotypes, best-guess genotypes must be used because the
approach does not currently handle genotypes in the form of
dosage. The EM algorithm currently employed for inferring
haplotypes works best for a moderate number of variants
(< 15), and very rare haplotypes (frequency< 0.1%) are rec-
ommended to be collapsed to ensure computation stability.
Despite these limitations, our approach has the potential to
250 Genetic Epidemiology, Vol. 40, No. 3, 244–252, 2016
shed some light on the relationship between traits and mul-
tiple associated SNVs in a region.
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